Benefits of Pulmonary Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Drug Treatment.
Yuji IwanamiKento EbiharaKeiko NakaoNaofumi SatoMidori MiyagiYasuhiko NakamuraSusumu SakamotoKazuma KishiSakae HommaSatoru EbiharaPublished in: Journal of clinical medicine (2022)
It was suggested that AFD treatment reduced exercise tolerance and HRQOL at 3 months; however, the concurrent use of PR may prevent or mitigate these effects.